
PSTV Stock Forecast & Price Target
PSTV Analyst Ratings
Bulls say
Plus Therapeutics is making promising strides in the development and commercialization of complex treatments for patients with cancer and rare diseases, particularly with their main programs targeting recurrent glioblastoma and leptomeningeal metastases. With a strong Q4 performance, a healthy balance sheet, and ongoing activities to push forward pivotal trials and optimize commercial efforts, the company appears to have a solid foundation for future growth and success. However, investors should be wary of potential risks related to the company's clinical and regulatory process, partnerships and financials, commercial success, legal and intellectual property, as well as market competition.
Bears say
Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing treatments for patients with cancer and rare diseases, specifically in the CNS space. While they have some promising products in their pipeline, such as the Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda), there are significant risks to their attainment of commercial success, including competition, changing macroeconomic factors, and regulatory approval. Additionally, the company's recent reverse stock split may signal capital market strain and could take time to repair their shareholder base. Despite advances in their pipeline, these risks contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PSTV Analyst Forecast & Price Prediction
Start investing in PSTV
Order type
Buy in
Order amount
Est. shares
0 shares